ClinicalTrials.gg
RecruitingNCT07496229Updated Oct 22, 2026

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)

A Phase 1/2 interventional study of GW5282 combined with Golidocitinib and GW5282 combined with Golidocitinib in T-cell Lymphomas, sponsored by Dizal Pharmaceuticals. Recruiting at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Dizal Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 22, 2026Enrollment updatedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Lymphoma, T-Cell with a site in China — 31 open to participants now, 34 under way, 4 of them phase 3. Lymphoma, T-Cell · China.

Planned enrollment
4th of 69
220 · median 38
Started
2026
with 2 others
Phase 1/2
12 of 75
6 open now
Primary completion
2029-09
later than 32 of 33 live
Registered
74th of 75
by date

Among the 75 studies in Lymphoma, T-Cell with a site in China, this one is the 4th largest by planned enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2026, is one of 12 in phase 1/2, reaches primary completion later than 32 of the 33 other live ones, and was the 74th registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

31 of the 75 studies in Lymphoma, T-Cell with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Lymphoma, T-Cell studies recruiting now, 41 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Lymphoma, T-Cell with a site in China, or all of them as a file.
02

Study summary

This is a phase 1/2 open-label study to evaluate GW5282 in combination with golidocitinib (G2 regimen) for the treatment of T-cell lymphoma. In the first phase of the study, the maximum tolerated dose will be determined through dose escalation; in the second phase, the potential therapeutic advantages of the novel combination therapy over the conventional CHOP regimen will be preliminarily assessed through a randomized controlled design.

03

Conditions studied

  • T-cell Lymphomas

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed ;
  2. Adult ≥ 18 years of age;
  3. performance status score ≤ 2;
  4. of not less than 12 weeks;
  5. Histopathologically confirmed diagnosis of PTCL;
  6. Presence of ;
  7. Adequate bone marrow function and vital organ function reserve;
  8. Ability to comply with study requirements and to complete study-related procedures;
  9. Adequate during participation in the trial.

Exclusion criteria

Exclusion Criteria:

  1. Presence of unresolved drug-related adverse events greater than Grade 1;
  2. Lymphoma involving the central nervous system;
  3. Failure to complete the required for other anti-tumor therapies;
  4. use that does not meet protocol requirements;
  5. Major surgery/trauma within a short period, or planned major surgery within a short period;
  6. Vaccination with a within a short period;
  7. Inability to discontinue prohibited medications;
  8. Requirement for agents or biologics due to an underlying disease;
  9. Presence of active infection;
  10. Significant cardiovascular disease;
  11. Presence of gastrointestinal disease that might affect drug intake or absorption;
  12. History of other ;
  13. Known allergy to the study drug;
  14. Other severe or uncontrolled systemic diseases;
  15. Personnel with a conflict of interest (e.g., site staff, sponsor employees);
  16. Pregnant or breastfeeding women;
  17. Inability to comply with protocol requirements.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Dose escalation cohorts (Part A, non-randomized)

    Drug: GW5282 combined with Golidocitinib

  • Experimental
    Dose expansion cohorts (Part B, randomized)

    Drug: GW5282 combined with Golidocitinib

  • Experimental
    Control cohort (Part B, randomized)

    Drug: Conventional CHOP regimen

  • Experimental
    Dose confirmation cohort (Part A, non-randomized)

    Drug: GW5282 combined with Golidocitinib

Interventions

  • DrugGW5282 combined with Golidocitinib

    Drug page: Golidocitinib

    GW5282 and Golidocitinib will be administered in combination as twice daily (BID) and once daily (QD), respectively. The starting dose will be GW5282 40 mg BID combined with golidocitinib 150 mg QD. If tolerated, the dose of GW5282 will be subsequently escalated.

  • DrugGW5282 combined with Golidocitinib

    Drug page: Golidocitinib

    GW5282 and Golidocitinib will be administered at the doses determined during escalation part.

  • DrugConventional CHOP regimen

    CHOP regimen includes the administrations of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

  • DrugGW5282 combined with Golidocitinib

    Drug page: Golidocitinib

    GW5282 and Golidocitinib will be administered at the doses determined during escalation part.

06

What researchers measure

Primary outcomes

  1. Part A: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).

    To evaluate the safety and tolerability of the combination of GW5282 and golidocitinib. Dose Limiting Toxicity (DLT) was evaluated in the DLT observation frame.

    Time frame: The DLT observation period is defined as the 21 days after the first dose.

  2. Part B: Complete Response Rate (CRR) According to Lugano 2014 by Investigators' Review

    To evaluate anti-tumor activity of GW5282 combined with golidocitinib as a chemo-free induction therapy for newly diagnosed PTCL, and compare it with conventional CHOP regimen.

    Time frame: Up to 6 cycles, each cycle is 21 days

Secondary outcomes

  1. Part A: Plasma concentration of GW5282 and golidocitinib

    To characterize the pharmacokinetics of GW5282 and golidocitinib when orally given together

    Time frame: C1D1, C1D15, and Day 1 of Cycle 2~9

  2. Part A: Efficacy parameters

    To assess anti-tumor efficacy of GW5282 combined with golidocitinib using endpoint: Objective Response Rate (ORR)

    Time frame: through the study completion, an average of around 1~2 years

  3. Part A: Efficacy parameters

    To assess anti-tumor efficacy of GW5282 combined with golidocitinib using endpoint: Complete Response Rate (CRR)

    Time frame: through the study completion, an average of around 1~2 years

  4. Part A: Efficacy parameters

    To assess anti-tumor efficacy of GW5282 combined with golidocitinib using endpoint: Duration of Response (DoR)

    Time frame: through the study completion, an average of around 1~2 years

  5. Part A: Efficacy parameters

    To assess anti-tumor efficacy of GW5282 combined with golidocitinib using endpoint: Progression Free Survival (PFS)

    Time frame: through the study completion, an average of around 1~2 years

  6. Part B: Other efficacy parameters

    To assess anti-tumor efficacy of GW5282 combined with golidocitinib using endpoint: ORR

    Time frame: through the study completion, an average of around 1~2 years

  7. Part B: Other efficacy parameters

    To assess anti-tumor efficacy of GW5282 combined with golidocitinib using endpoint: DoR

    Time frame: through the study completion, an average of around 1~2 years

  8. Part B: Other efficacy parameters

    To assess anti-tumor efficacy of GW5282 combined with golidocitinib using endpoints: PFS.

    Time frame: through the study completion, an average of around 1~2 years

  9. Part B: Adverse Events (AEs) / Serious Adverse Events (SAEs)

    To determine the safety and tolerability of GW5282 combined with golidocitinib: Number of Participants With AEs, Number of Participants With SAEs. Using investigator reported AEs according to CTCAE and SAE criteria.

    Time frame: through the study completion, an average of around 1~2 years

  10. Part B: Plasma concentration of GW5282 and golidocitinib

    To characterize the pharmacokinetics of GW5282 and golidocitinib when orally given together

    Time frame: C1D1, C1D15, and Day 1 of subsequent cycles till treatment discontinuation

07

Study locations

1 of 12 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2029, 41 months after the start.

Of 29 phase 1/2 interventional studies under Lymphoma, T-Cell, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 92. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 27, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Dec 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
165→220
Oct 22, 2026
Interventions
Added Drug: GW5282 combined with Golidocitinib. Arms added: Dose confirmation cohort (Part A, non-randomized)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Enrollment 165→220
    Interventions Added Drug: GW5282 combined with Golidocitinib. Arms added: Dose confirmation cohort (Part A, non-randomized)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07496229
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Apr 15, 2026
Primary completion
Sep 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

Jingrun Li
Contact
jingrun.li@dizalpharma.com
+86-21-61097800

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golidocitinib

Start the discussion